Jan Kubeš

Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation

Eduard Jirkovský, Anna Jirkovská, Hana Bavlovič Piskáčková et al. · Circulation Heart Failure · 2021 · 58 citations · Full text

Medicine, Cardiology, Pharmacology +17

Hydrophobicity‐enhanced ferritin nanoparticles for efficient encapsulation and targeted delivery of hydrophobic drugs to tumor cells

Alessio Incocciati, Jan Kubeš, Roberta Piacentini et al. · Protein Science · 2023 · 25 citations · Full text

Pharmacy, Biochemistry, Pharmaceutics +17

Structure–Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIβ Interactions

Anna Jirkovská, Galina Karabanovich, Jan Kubeš et al. · Journal of Medicinal Chemistry · 2021 · 23 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase IIβ Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity

Petra Kollárová-Brázdová, Anna Jirkovská, Galina Karabanovich et al. · Journal of Pharmacology and Experimental Therapeutics · 2020 · 20 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

2,6-Disubstituted 7-(naphthalen-2-ylmethyl)-7H-purines as a new class of potent antitubercular agents inhibiting DprE1

Vladimír Finger, Tomáš Kučera, Radka Kafková et al. · European Journal of Medicinal Chemistry · 2023 · 18 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16